Insider Transactions in Q2 2023 at Syndax Pharmaceuticals Inc (SNDX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2023
|
Keith A. Goldan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
577
-18.0%
|
$12,694
$22.31 P/Share
|
|
Jun 09
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-48.05%
|
$1,109,955
$21.18 P/Share
|
|
Jun 09
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+32.63%
|
$369,985
$7.58 P/Share
|
|
May 09
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-74.77%
|
$1,109,955
$21.41 P/Share
|
|
May 09
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+42.78%
|
$317,130
$6.38 P/Share
|
|
Apr 10
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-74.77%
|
$1,004,245
$19.53 P/Share
|
|
Apr 10
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+42.78%
|
$317,130
$6.38 P/Share
|